Fear mongering jeopardizing “21st Century” trade deal, says Medicines Australia

16 March 2015

The Trans Pacific Partnership Agreement (TPP) will open up vast new markets for Australian companies, including manufacturers of innovative medicines and vaccines, says trade group Medicines Australia’s chief executive, Tim James.

“Pharmaceuticals are already one of Australia’s largest manufactured export, worth around A$3 billion ($2.29 billion) each year, he said, adding: “But a new trade deal which further reduces trade barriers, improves market access and, above all, establishes high regional standards for intellectual property (IP) protection, could help transform Australia into a leading global hub for researching and manufacturing a new generation of highly specialized medicines and vaccines.”

In recent weeks, critics have appeared in the media claiming that possible changes to Australia’s IP system as a result of the TPP will lead to higher prices for medicines and “decimate” the Pharmaceutical Benefits Scheme (PBS).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical